Skip to main content
. 2020 Dec 23;23(6):894–904. doi: 10.1093/neuonc/noaa285

Fig. 2.

Fig. 2

A) Forest plot of pooled incidence rate (patient-years) for HER2+ MBC. Random effects model presented. Incidence per year of follow-up ranged from 0.04 to 0.27. Median follow-up times ranged from 5.8 to 53.6 months. B) Funnel Plot for publication bias according to studies reporting brain metastasis in HER2+ MBC. Egger’s test; P = 0.30. HER2+, human epidermal growth factor receptor-2 positive; MBC, metastatic breast cancer.